These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6253094)

  • 1. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG; Makuch RW; Strong JM; Glatstein E
    Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration of misonidazole and peripheral neuropathy.
    Marten TR
    Am J Clin Oncol; 1982 Apr; 5(2):239-40. PubMed ID: 6283876
    [No Abstract]   [Full Text] [Related]  

  • 4. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experiences with the radiosensitizer Misonidazol (author's transl)].
    Bamberg M; Tamulevicius P; Streffer C; Scherer E
    Strahlentherapie; 1981 Aug; 157(8):524-36. PubMed ID: 7268822
    [No Abstract]   [Full Text] [Related]  

  • 7. The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies.
    Bleehen NM
    Cancer Clin Trials; 1980; 3(3):267-73. PubMed ID: 7002338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of misonidazole.
    Notter G; Rylander U; Turesson I
    Strahlentherapie; 1980; 156(10):714-8. PubMed ID: 7434379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misonidazole neuropathy.
    Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
    Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity.
    Jones DH; Bleehen NM; Workman P; Smith NC
    Br J Radiol; 1983 Nov; 56(671):865-70. PubMed ID: 6626878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.
    Wasserman TH; Phillips TL; Van Raalte G; Urtasun R; Partington J; Koziol D; Schwade JG; Gangji D; Strong JM
    Br J Radiol; 1980 Feb; 53(626):172-3. PubMed ID: 6245744
    [No Abstract]   [Full Text] [Related]  

  • 13. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole. -End results of a multicentric controlled German study].
    Sack H; Calcanis A; Godehardt E; Weidtman V; Zülch KJ; Ammon J; Bamberg M; Herbst M; Keim H; Kleibel F; Makoski HB; Potthoff PC; Schlegel G; Schnepper E
    Strahlentherapie; 1982 Aug; 158(8):466-9. PubMed ID: 6753245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misonidazole Neuropathy: a clinical, electrophysiological, and histological study.
    Melgaard B; Hansen HS; Kamieniecka Z; Paulson OB; Pedersen AG; Tang X; Trojaborg W
    Ann Neurol; 1982 Jul; 12(1):10-7. PubMed ID: 7114817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is misonidazole neurotoxicity altered by the use of phenytoin and/or dexamethasone in RTOG 79-18 and RTOG 79-16?
    Nelson DF; Gillespie BW; Diener MD; Davis DR; Wasserman T; Phillips TL; Stetz J
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1731-4. PubMed ID: 6384162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misonidazole in patients receiving radical radiotherapy: pharmacokinetic effects of phenytoin, tumor response and neurotoxicity.
    Moore JL; Paterson IC; Dawes PJ; Henk JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):361-4. PubMed ID: 7107352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.